Cognitive, Emotional, Physical and Psychosocial Effects of Panax Quinquefolius L

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the efficacy and safety of REMEMBER-fX (HT1001, an extract of Panax quinquefolius) in a human sample using standard clinical neuropsychological instruments and side effects rating scales.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: CV Technologies

Criteria

Inclusion Criteria:

• Healthy men and women between the age of 35 - 75

• Women of child bearing capacity who agree to use an acceptable form of birth control during the trial (i.e. oral contraception, reliable use of a double-barrier method (e.g. condom and diaphragm, condom and foam, condom and sponge), IUD or tubal ligation)

• Achievement Test (WRAT-III) score greater than 70 with a reading level within normal limits as defined by a Wide Range

• Willing to adhere to the requirements of the protocol, including availability for follow-up visits

• Willing and able to sign written informed consent

Exclusion Criteria:

• Medical conditions;

• HIV/AIDS

• Malignancy (under active observation or treatment)

• Unstable cardiovascular disease (physician visit or hospitalization for unstable cardiovascular disease in the last 6 mo.)

• Renal Abnormalities (serum creatinine known to be > 200umol/L)

• Acute or active chronic liver disease

• Diabetes

• Neurologic or psychiatric disease (progressive or currently under treatment)

• Active tuberculosis

• Multiple sclerosis

• Bleeding disorders